Avinza: Phase III results, marketed to treat chronic pain

In a Phase III trial in 295 patients, Avinza significantly reduced pain from baseline at 4 weeks compared to placebo. Avinza gave a 17% and 20% improvement on the WOMAC OA Index Pain Visual Analogue S...